Minnesota Oncology Hematology, PA
Minnesota Oncology Hematology, PA was paid $8.13M by Medicaid between Jan 2018 and Nov 2024, across 77 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 20% of everything it billed.
33Billing provider infoMINNESOTA ONCOLOGY HEMATOLOGY, PA
SAINT PAUL, MN 55114
SAINT PAUL, MN 55114
33aNPI1528035995assigned 03/03/2006
33bProvider typeRegistered Dietitian
28Total paid$8.13M
24GClaims265,013
24DCodes billed77
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Registered Dietitian providers in Minnesota
Rank by total paid#3 of 13
Median peer was paid$206K
This provider vs. median39×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 50,562 | $451K | |
| 2019 | 54,813 | $1.65M | |
| 2020 | 51,442 | $2.33M | |
| 2021 | 58,192 | $2.07M | |
| 2022 | 29,539 | $1.17M | |
| 2023 | 16,880 | $404K | |
| 2024incomplete | 3,585 | $60K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 20% | 32,246 | 24,317 | $1.61M |
| J9271 | Injection, pembrolizumab, 1 mg | 20% | 279 | 192 | $1.60M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 14% | 19,152 | 10,466 | $1.13M |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 7.0% | 7,993 | 6,125 | $571K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 5.5% | 12,491 | 10,656 | $449K |
| J2469 | Injection, palonosetron hcl, 25 mcg | 3.2% | 5,527 | 3,225 | $257K |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 3.1% | 580 | 380 | $249K |
| J1453 | Injection, fosaprepitant, 1 mg | 3.0% | 1,962 | 1,210 | $241K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.9% | 41,663 | 29,484 | $234K |
| 80053 | Comprehensive metabolic panel | 2.6% | 27,874 | 21,735 | $209K |
| 96367 | 2.2% | 10,333 | 5,358 | $181K | |
| J0185 | Injection, aprepitant, 1 mg | 2.2% | 943 | 581 | $179K |
65 more codes
| 96375 | Therapeutic injection; each additional sequential IV push | 1.7% | 12,735 | $142K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.6% | 3,425 | $126K |
| J2505 | Injection, pegfilgrastim, 6 mg | 1.5% | 91 | $122K |
| 96417 | 1.4% | 2,994 | $111K | |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 1.1% | 185 | $88K |
| 36415 | Collection of venous blood by venipuncture | 1.0% | 35,168 | $84K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 689 | $58K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 1,552 | $56K |
| 82728 | <1% | 5,029 | $54K | |
| J3490 | Unclassified drugs | <1% | 597 | $40K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,463 | $32K |
| 96415 | <1% | 1,537 | $30K | |
| 83550 | <1% | 3,753 | $26K | |
| 99205 | Prolong outpt/office vis | <1% | 267 | $22K |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 317 | $21K |
| 99223 | Prolong inpt eval add15 m | <1% | 193 | $19K |
| 83540 | <1% | 3,760 | $19K | |
| 96411 | <1% | 506 | $19K | |
| 82378 | <1% | 1,186 | $19K | |
| 80050 | General health panel | <1% | 340 | $16K |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 762 | $14K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,149 | $12K |
| 83615 | <1% | 2,752 | $12K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 10,536 | $8K |
| 86300 | <1% | 529 | $8K | |
| 85046 | <1% | 1,521 | $7K | |
| 96416 | <1% | 79 | $5K | |
| 82607 | <1% | 367 | $5K | |
| 96402 | <1% | 312 | $5K | |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 310 | $4K |
| J3489 | Injection, zoledronic acid, 1 mg | <1% | 153 | $4K |
| 82784 | <1% | 182 | $4K | |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 86 | $3K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 110 | $3K |
| 99442 | <1% | 68 | $3K | |
| 99443 | <1% | 45 | $3K | |
| J9267 | Injection, paclitaxel, 1 mg | <1% | 220 | $3K |
| J1626 | Injection, granisetron hydrochloride, 100 mcg | <1% | 978 | $2K |
| 84165 | <1% | 229 | $2K | |
| 82565 | <1% | 441 | $2K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 814 | $2K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 129 | $2K |
| J9045 | Injection, carboplatin, 50 mg | <1% | 95 | $2K |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 88 | $2K |
| J9263 | Injection, oxaliplatin, 0.5 mg | <1% | 35 | $872.89 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,793 | $806.75 |
| 96368 | <1% | 61 | $772.19 | |
| 83883 | <1% | 27 | $670.16 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 75 | $630.12 |
| 81002 | <1% | 195 | $614.47 | |
| 90688 | <1% | 39 | $547.58 | |
| 36591 | <1% | 56 | $461.44 | |
| 85027 | <1% | 87 | $379.31 | |
| 82746 | <1% | 28 | $375.92 | |
| 99441 | <1% | 13 | $256.33 | |
| G0008 | Administration of influenza virus vaccine | <1% | 50 | $249.27 |
| S0028 | Injection, famotidine, 20 mg | <1% | 462 | $241.30 |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 41 | $210.96 |
| 84153 | <1% | 16 | $210.89 | |
| 90686 | <1% | 30 | $175.64 | |
| 83735 | <1% | 43 | $13.46 | |
| G9002 | Coordinated care fee, maintenance rate | 0% | 109 | $0.00 |
| 90662 | 0% | 16 | $0.00 | |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | 0% | 36 | $0.00 |
| 86304 | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGESME, DEAN (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Minnesota Oncology Hematology, PA | Saint Paul, MN | $33K |
| Minnesota Oncology Hematology, PA | Maplewood, MN | $2K |
| Minnesota Oncology Hematology, PA | Edina, MN | $843.54 |
| Minnesota Oncology Hematology, PA | Burnsville, MN | $105.62 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.